A 14 Day Early Bactericidal Activity Study of Nitazoxanide for the Treatment of Tuberculosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-02-29

Study Completion Date

2018-04-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This research is being done to determine if Nitazoxanide (NTZ) will cause a significant decrease in the number of M. tuberculosis bacteria in sputum after 14 days of treatment. The study is being conducted at the GHESKIO Centers in Port au Prince Haiti

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Concomitant Infections of Mansonella Perstans in Tuberculosis and Buruli Ulcer Disease Patients From Ghana

NCT02281643

Mansonella Perstans Infection Buruli Ulcer Tuberculosis +1 more

COMPLETED PHASE2

TMC207-C202: Study to Evaluate Bactericidal Activity of Multiple Oral Doses of TMC207 in Subjects With Sputum-Smear Positive Tuberculosis

NCT00523926

Tuberculosis

COMPLETED PHASE2

The Efficacy and Adverse Reactions of Neotetracycline in the Treatment of GNB Infections

NCT06990126

Clinical Efficacy and Safety

ENROLLING_BY_INVITATION

Safety, False-Positive Reactions and Sensitizing Properties of Leishmania Tropica Skin Test Antigen

NCT00633009

Cutaneous Leishmaniasis

COMPLETED PHASE2

Clinical Evaluation of the Residual Antimicrobial Activity

NCT04495920

Bacterial Overgrowth

COMPLETED EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective randomized two-arm 14-day, early bactericidal activity study in treatment-naive, drug-susceptible patients with uncomplicated pulmonary tuberculosis (TB). The study will be conducted at the GHESKIO Centers in Port au Prince Haiti. Twenty patients will be randomized to receive NTZ 1 gram orally twice daily for 14 days. Ten patients will be randomized as positive controls to receive standard 4 drug tuberculosis therapy with isoniazid (H), rifampin (R), ethambutol (E), and pyrazinamide (PZA). Patients' sputum will be collected before and then every two days during 14 days of treatment, and the primary endpoint will be the change in the number of M. tuberculosis in patients' sputum. Our primary hypothesis is that NTZ will result in a significant decrease in the number of M. tuberculosis in sputum during14 days of treatment. The number of M. tuberculosis will be quantified by the time to positive (TTP) signal in hours in an automated liquid media culture system (BACTEC MGIT 960, Becton Dickinson).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tuberculosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Nitazoxanide

Participants with drug-sensitive tuberculous randomized to the NTZ arm will receive nitazoxanide 1000 mg po twice daily for 14 days. After this time point, participants will be switched to WHO standard tuberculosis therapy with isoniazid, rifampin, pyrazinamide and ethambutol.

Group Type EXPERIMENTAL

Nitazoxanide

Intervention Type DRUG

nitazoxanide 1000 mg orally twice daily with food for 14 days

Control

Participants with drug-sensitive tuberculosis randomized to the standard therapy arm will receive WHO standard tuberculosis therapy involving isoniazid 300 mg po daily, rifampin 600 mg po daily, pyrazinamide 25 mg/kg po daily and ethambutol 15 mg/kg po daily.

Group Type OTHER

Control

Intervention Type OTHER

The control arm will receive WHO standard therapy for tuberculosis with isoniazid, rifampin, pyrazinamide, and ethambutol

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nitazoxanide

nitazoxanide 1000 mg orally twice daily with food for 14 days

Intervention Type DRUG

Control

The control arm will receive WHO standard therapy for tuberculosis with isoniazid, rifampin, pyrazinamide, and ethambutol

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Nizonide Alinia

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women ages 18 - 65
* Diagnosed with pulmonary tuberculosis via: sputum-microscopy smear-positive (2+ or 3+) within 14 days plus Sputum GeneXpert positive within 14 days plus Chest radiograph consistent with M. tuberculosis within 14 days
* TB treatment naïve at time of enrollment
* Bodyweight \> 40kg
* Negative HIV test within 30 days
* Able to complete activities of daily living (ADLs)
* All participants must agree not to participate in a conception process (i.e. active attempt to become pregnant or to impregnate, donate sperm, in vitro fertilization)
* All female participants must agree to use barrier methods such as condoms as well as hormonal contraception for dual prophylaxis.
* Able to give informed consent and demonstrate understanding of this study and willingness to participate in this study
* Willing to be hospitalized for 2 weeks

Exclusion Criteria

* Pregnancy
* Evidence of complications of M. tuberculosis such as hemoptysis or shortness of breath
* Extrapulmonary manifestations of M. tuberculosis
* History of prior active tuberculosis
* Evidence of rifampin resistance via GeneXpert
* Previous diagnosis of diabetes or suggestion of impaired glucose metabolism via random plasma glucose
* Previous diagnosis of HIV by any rapid HIV test or by ELISA
* Any of the following lab abnormalities: Creatinine \> 1.5 times the ULN; Random glucose \> 2 times the ULN; ALT, AST, or alkaline phosphatase \> 2 times the ULN; Hemoglobin \< 7.5 g/dL
* Any participant currently taking antimycobacterial therapy or within the past 30 days
* Any concomitant illness that could compromise patient safety in this trial such as renal failure, chronic liver disease or alcoholic dependency
* Enrolled in another clinical trial

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No